Drug-Coated Stent Competition Unlikely To Immediately Lower Prices – Cordis
This article was originally published in The Gray Sheet
Executive Summary
The Centers for Medicare & Medicaid Services should increase the price difference between drug-eluting and bare-metal stents to $3,024 - $1,539 more than the rate suggested in the hospital IPPS proposed rule, according to Johnson & Johnson/Cordis
You may also be interested in...
Drug-Eluting Stent DRGs Sustained At FY 2003 Rates – IPPS Final Rule
CMS will maintain the current DRG weights for drug-eluting stents in FY 2004, contending it is not "appropriate" to use anticipated Oct. 1 charges to set payment rates, according to the hospital 1IPPS final rule
Drug-Eluting Stent DRGs Sustained At FY 2003 Rates – IPPS Final Rule
CMS will maintain the current DRG weights for drug-eluting stents in FY 2004, contending it is not "appropriate" to use anticipated Oct. 1 charges to set payment rates, according to the hospital 1IPPS final rule
DES Makers, Hospitals Will Not Get Higher-Paying DRG In FY 2004 – Scully
Competition provided by additional drug-eluting stent players in the U.S. ultimately will drive down pricing, making it unnecessary to further increase reimbursement for the technology in FY 2004, CMS Administrator Tom Scully asserted